• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SCNX

    Scienture Holdings Inc.

    Subscribe to $SCNX
    $SCNX
    Other Pharmaceuticals
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Scienture Holdings Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Scienture Holdings Inc. SEC Filings

    View All

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    9/23/25 5:01:18 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Scienture Holdings Inc.

    424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

    9/19/25 5:15:16 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Scienture Holdings Inc.

    EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

    8/28/25 12:15:25 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B3 filed by Scienture Holdings Inc.

    424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

    8/27/25 5:29:56 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form SCHEDULE 13G filed by Scienture Holdings Inc.

    SCHEDULE 13G - Scienture Holdings, Inc. (0001382574) (Subject)

    8/20/25 7:21:15 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    8/15/25 5:10:42 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Scienture Holdings Inc.

    424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

    8/15/25 10:37:17 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Scienture Holdings Inc.

    10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

    8/12/25 8:50:52 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Scienture Holdings Inc.

    EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

    8/11/25 12:15:30 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form D/A filed by Scienture Holdings Inc.

    D/A - Scienture Holdings, Inc. (0001382574) (Filer)

    8/7/25 5:30:42 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

    Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced

    10/1/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

    Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized a major commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement

    9/16/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

    Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million bef

    8/14/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

    COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesa

    8/13/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

    Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company's common stock to institutional or accredited investors. The bridge funding does not include any other obli

    7/24/25 5:12:00 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

    Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has received a notification letter from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of the Company's common stock has been at $1.00 per share or greater for the previous ten consecutive business days. As

    7/16/25 8:15:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Announces Cancelation of ELOC

    TAMPA, FL, June 17, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit ("ELOC") facility effective as of May 22, 2025. In connection with cancellation of the ELOC, on June 16, 2025, the Company filed a post-effective amendment to the Registration Statement on Form S-1 (File No. 333-283591) filed with the Securities and Exchange Commission on Dec

    6/17/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

    TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan potassium) Ora

    5/19/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

    TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC

    4/22/25 8:04:59 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care